👀 Ones to watch: The MOST undervalued stocks to buy right nowSee Undervalued Stocks

Japanese shares end lower on tech sell-off, pandemic worries

Published 11/05/2021, 08:39
Updated 11/05/2021, 08:42
© Reuters.
JP225
-
TOPX
-
4507
-
2802
-
6752
-
3436
-
6857
-
9984
-
MTHR
-

TOKYO, May 11 (Reuters) - Japanese shares tumbled on
Tuesday, dragged down by technology stocks tracking overnight
Wall Street losses, while domestic cyclical stocks also fell on
concerns around the nation's worsening situation of the
pandemic.
The Nikkei share average .N225 tumbled 3.08% to 28,608.59,
its lowest closing level since March 24, while the broader Topix
.TOPX lost 2.37% to 1,905.92. Both marked their biggest fall
since Feb. 26, while the Nikkei closed below its 100-day moving
average.
Wall Street closed lower on Monday as inflation concerns
drove investors away from market-leading growth stocks in favour
of cyclicals. .N
The prolonged pandemic added to the negative sentiment, with
calls for expanding the state of emergency, which covers major
prefectures such as Tokyo and Osaka.
Some prefectural governors called for stronger emergency
measures to be put in place nationwide, the Kyodo news agency
reported. "Atmosphere in the market is bad," said Shoichi Arisawa,
general manager of the investment research department at
IwaiCosmo Securities.
"Even domestic cyclical shares, which should be bought on
the day like today, were being sold. Investors could not find
any reasons to buy Japanese stocks at a time when the pandemic
in Japan shows little signs for slowing down."
Leading tech shares fell, with SoftBank Group 9984.T
tumbling 6.51%.
Among hot chip-related shares, Advantest 6857.T lost 5.5%
while Sumco 3436.T shed 5.4%
Panasonic 6752.T lost 5.8% after its earnings fell short
of expectations. Mothers start-up shares index .MTHR lost 3.46% to hit its
lowest close since late August.
About 90% of shares on the Tokyo Stock Exchange's main board
declined while only 7% of them rose.
Among gainers, Shionogi & Co 4507.T inched up 1.2% after a
local media report that said the drug maker may start supplying
COVID-19 vaccines later this year. Ajinomoto 2802.T rose 3.8% after its earnings beat
analysts estimates and announced share buy-back.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2024 - Fusion Media Limited. All Rights Reserved.